A Phase 1 interventional study of AZD2423 and Placebo in Healthy Volunteer, sponsored by AstraZeneca. Completed at 2 sites in United Kingdom. Open to participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-03-18.
Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science
This is a Phase I, single centre, randomised, double-blind, placebo-controlled, parallel group study to assess the safety, tolerability and pharmacokinetics of AZD2423 following single ascending dose administration to healthy Japanese subjects.
AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: AZD2423
Drug: Placebo
oral solution, single dose
oral solution,single dose
To asses the safety: Adverse events, vital signs, electrocardiograms (ECGs), laboratory variables.
Time frame: From screening period to follow-up visit, 40 days (Maximum).
To characterize the pharmacokinetics of AZD2423 in plasma and urine.
Time frame: Blood and urine sampling from pre-dose until follow-up visit, 10 days (approximately)
Exploratory endpoints;Levels of CCL2 pre-and post dose
Time frame: Blood sampling after dosing, 3 days
This study is completed, as verified in Mar 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca